Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 98

1.

Circulating Exosomal miR-141-3p and miR-375 in Metastatic Progression of Rectal Cancer.

Meltzer S, Bjørnetrø T, Lyckander LG, Flatmark K, Dueland S, Samiappan R, Johansen C, Kalanxhi E, Ree AH, Redalen KR.

Transl Oncol. 2019 Aug;12(8):1038-1044. doi: 10.1016/j.tranon.2019.04.014. Epub 2019 May 27.

2.

High level of circulating vitamin D during neoadjuvant therapy may lower risk of metastatic progression in high-risk rectal cancer.

Abrahamsson H, Porojnicu AC, Lindstrøm JC, Dueland S, Flatmark K, Hole KH, Seierstad T, Moan J, Redalen KR, Meltzer S, Ree AH.

BMC Cancer. 2019 May 23;19(1):488. doi: 10.1186/s12885-019-5724-z.

3.

A Three-dimensional Ex Vivo Viability Assay Reveals a Strong Correlation Between Response to Targeted Inhibitors and Mutation Status in Melanoma Lymph Node Metastases.

Flørenes VA, Flem-Karlsen K, McFadden E, Bergheim IR, Nygaard V, Nygård V, Farstad IN, Øy GF, Emilsen E, Giller-Fleten K, Ree AH, Flatmark K, Gullestad HP, Hermann R, Ryder T, Wernhoff P, Mælandsmo GM.

Transl Oncol. 2019 Jul;12(7):951-958. doi: 10.1016/j.tranon.2019.04.001. Epub 2019 May 13.

4.

ImmunoPeCa trial: Long-term outcome following intraperitoneal MOC31PE immunotoxin treatment in colorectal peritoneal metastasis.

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Julsrud L, Fodstad Ø, Dueland S, Flatmark K.

Eur J Surg Oncol. 2019 Apr 22. pii: S0748-7983(19)30406-8. doi: 10.1016/j.ejso.2019.04.014. [Epub ahead of print] Review.

PMID:
31036394
5.

Laparoscopic versus open liver resection in the posterosuperior segments: a sub-group analysis from the OSLO-COMET randomized controlled trial.

Aghayan DL, Fretland ÅA, Kazaryan AM, Sahakyan MA, Dagenborg VJ, Bjørnbeth BA, Flatmark K, Kristiansen R, Edwin B.

HPB (Oxford). 2019 Apr 5. pii: S1365-182X(19)30480-0. doi: 10.1016/j.hpb.2019.03.358. [Epub ahead of print]

PMID:
30962136
6.

Integrative genomic analysis of peritoneal malignant mesothelioma: understanding a case with extraordinary chemotherapy response.

Lund-Andersen C, Nakken S, Nygård S, Fromm B, Aasheim LB, Davidson B, Julsrud L, Abrahamsen TW, Kristensen AT, Dybdahl B, Larsen SG, Hovig E, Flatmark K.

Cold Spring Harb Mol Case Stud. 2019 Apr 1;5(2). pii: a003566. doi: 10.1101/mcs.a003566. Print 2019 Apr.

7.

Responsiveness to PD-1 Blockade in End-Stage Colon Cancer with Gene Locus 9p24.1 Copy-Number Gain.

Ree AH, Nygaard V, Russnes HG, Heinrich D, Nygaard V, Johansen C, Bergheim IR, Hovig E, Beiske K, Negård A, Børresen-Dale AL, Flatmark K, Mælandsmo GM.

Cancer Immunol Res. 2019 May;7(5):701-706. doi: 10.1158/2326-6066.CIR-18-0777. Epub 2019 Feb 25.

PMID:
30804006
8.

Cabazitaxel-loaded Poly(2-ethylbutyl cyanoacrylate) nanoparticles improve treatment efficacy in a patient derived breast cancer xenograft.

Fusser M, Øverbye A, Pandya AD, Mørch Ý, Borgos SE, Kildal W, Snipstad S, Sulheim E, Fleten KG, Askautrud HA, Engebraaten O, Flatmark K, Iversen TG, Sandvig K, Skotland T, Mælandsmo GM.

J Control Release. 2019 Jan 10;293:183-192. doi: 10.1016/j.jconrel.2018.11.029. Epub 2018 Dec 4.

9.

Markers of Mitochondrial Metabolism in Tumor Hypoxia, Systemic Inflammation, and Adverse Outcome of Rectal Cancer.

Bousquet PA, Meltzer S, Sønstevold L, Esbensen Y, Dueland S, Flatmark K, Sitter B, Bathen TF, Seierstad T, Redalen KR, Eide L, Ree AH.

Transl Oncol. 2019 Jan;12(1):76-83. doi: 10.1016/j.tranon.2018.09.010. Epub 2018 Sep 29.

10.

Systemic immune response induced by oxaliplatin-based neoadjuvant therapy favours survival without metastatic progression in high-risk rectal cancer.

Kalanxhi E, Meltzer S, Schou JV, Larsen FO, Dueland S, Flatmark K, Jensen BV, Hole KH, Seierstad T, Redalen KR, Nielsen DL, Ree AH.

Br J Cancer. 2018 May;118(10):1322-1328. doi: 10.1038/s41416-018-0085-y. Epub 2018 Apr 26.

11.

Beyond total mesorectal excision in locally advanced rectal cancer with organ or pelvic side-wall involvement.

Mariathasan AB, Boye K, Giercksky KE, Brennhovd B, Gullestad HP, Emblemsvåg HL, Grøholt KK, Dueland S, Flatmark K, Larsen SG.

Eur J Surg Oncol. 2018 Aug;44(8):1226-1232. doi: 10.1016/j.ejso.2018.03.029. Epub 2018 Apr 12.

PMID:
29691115
12.

Low dose-rate irradiation with [3H]-labelled valine to selectively target hypoxic cells in a human colorectal cancer xenograft model.

Mikalsen SG, Mikalsen LTG, Sandvik JA, Aarnes EK, Fenne S, Flatmark K, Lyng H, Edin NFJ, Pettersen EO.

Acta Oncol. 2018 Sep;57(9):1216-1224. doi: 10.1080/0284186X.2018.1457223. Epub 2018 Apr 9.

PMID:
29630428
13.

Vertical Rectus Abdominis Musculocutaneous Flap Repair Improves Perineal Wound Healing after Abdominoperineal Resection for Irradiated Locally Advanced Rectal Cancer.

Spasojevic M, Mariathasan AB, Goscinski M, Thorgersen EB, Solbakken AM, Gullestad HP, Ryder T, Flatmark K, Larsen SG.

Ann Surg Oncol. 2018 May;25(5):1357-1365. doi: 10.1245/s10434-018-6363-3. Epub 2018 Mar 1.

PMID:
29497909
14.

Ceramide-containing liposomes with doxorubicin: time and cell-dependent effect of C6 and C12 ceramide.

Øverbye A, Holsæter AM, Markus F, Škalko-Basnet N, Iversen TG, Torgersen ML, Sønstevold T, Engebraaten O, Flatmark K, Mælandsmo GM, Skotland T, Sandvig K.

Oncotarget. 2017 Aug 12;8(44):76921-76934. doi: 10.18632/oncotarget.20217. eCollection 2017 Sep 29.

15.

Molecular signatures reflecting microenvironmental metabolism and chemotherapy-induced immunogenic cell death in colorectal liver metastases.

Østrup O, Dagenborg VJ, Rødland EA, Skarpeteig V, Silwal-Pandit L, Grzyb K, Berstad AE, Fretland ÅA, Mælandsmo GM, Børresen-Dale AL, Ree AH, Edwin B, Nygaard V, Flatmark K.

Oncotarget. 2017 Jul 18;8(44):76290-76304. doi: 10.18632/oncotarget.19350. eCollection 2017 Sep 29.

16.

MOC31PE immunotoxin - targeting peritoneal metastasis from epithelial ovarian cancer.

Andersson Y, Haavardtun SI, Davidson B, Dørum A, Fleten KG, Fodstad Ø, Flatmark K.

Oncotarget. 2017 Jun 27;8(37):61800-61809. doi: 10.18632/oncotarget.18694. eCollection 2017 Sep 22.

17.

Implementing precision cancer medicine in the public health services of Norway: the diagnostic infrastructure and a cost estimate.

Ree AH, Russnes HG, Heinrich D, Dueland S, Boye K, Nygaard V, Silwal-Pandit L, Østrup O, Hovig E, Nygaard V, Rødland EA, Nakken S, Øien JT, Johansen C, Bergheim IR, Skarpeteig V, Sathermugathevan M, Sauer T, Lund-Iversen M, Beiske K, Nasser S, Julsrud L, Reisse CH, Ruud EA, Flørenes VA, Hagene KT, Aas E, Lurås H, Johnsen-Soriano S, Geitvik GA, Lingjærde OC, Børresen-Dale AL, Mælandsmo GM, Flatmark K.

ESMO Open. 2017 May 2;2(2):e000158. doi: 10.1136/esmoopen-2017-000158. eCollection 2017.

18.

Laparoscopic Versus Open Resection for Colorectal Liver Metastases: The OSLO-COMET Randomized Controlled Trial.

Fretland ÅA, Dagenborg VJ, Bjørnelv GMW, Kazaryan AM, Kristiansen R, Fagerland MW, Hausken J, Tønnessen TI, Abildgaard A, Barkhatov L, Yaqub S, Røsok BI, Bjørnbeth BA, Andersen MH, Flatmark K, Aas E, Edwin B.

Ann Surg. 2018 Feb;267(2):199-207. doi: 10.1097/SLA.0000000000002353.

PMID:
28657937
19.

Immunoregulatory protein B7-H3 promotes growth and decreases sensitivity to therapy in metastatic melanoma cells.

Flem-Karlsen K, Tekle C, Andersson Y, Flatmark K, Fodstad Ø, Nunes-Xavier CE.

Pigment Cell Melanoma Res. 2017 Sep;30(5):467-476. doi: 10.1111/pcmr.12599. Epub 2017 Jul 4.

PMID:
28513992
20.

Diffusion-weighted magnetic resonance imaging of rectal cancer: tumour volume and perfusion fraction predict chemoradiotherapy response and survival.

Bakke KM, Hole KH, Dueland S, Grøholt KK, Flatmark K, Ree AH, Seierstad T, Redalen KR.

Acta Oncol. 2017 Jun;56(6):813-818. doi: 10.1080/0284186X.2017.1287951. Epub 2017 Feb 17.

PMID:
28464745
21.

Pathway-based classification of breast cancer subtypes.

Graudenzi A, Cava C, Bertoli G, Fromm B, Flatmark K, Mauri G, Castiglioni I.

Front Biosci (Landmark Ed). 2017 Jun 1;22:1697-1712.

PMID:
28410140
22.

Novel Treatment with Intraperitoneal MOC31PE Immunotoxin in Colorectal Peritoneal Metastasis: Results From the ImmunoPeCa Phase 1 Trial.

Frøysnes IS, Andersson Y, Larsen SG, Davidson B, Øien JT, Olsen KH, Giercksky KE, Julsrud L, Fodstad Ø, Dueland S, Flatmark K.

Ann Surg Oncol. 2017 Jul;24(7):1916-1922. doi: 10.1245/s10434-017-5814-6. Epub 2017 Feb 21.

PMID:
28224367
23.

Use of non-invasive imaging to monitor response to aflibercept treatment in murine models of colorectal cancer liver metastases.

Fleten KG, Bakke KM, Mælandsmo GM, Abildgaard A, Redalen KR, Flatmark K.

Clin Exp Metastasis. 2017 Jan;34(1):51-62. doi: 10.1007/s10585-016-9829-3. Epub 2016 Nov 3.

PMID:
27812769
24.

Expression and clinical significance of Wee1 in colorectal cancer.

Egeland EV, Flatmark K, Nesland JM, Flørenes VA, Mælandsmo GM, Boye K.

Tumour Biol. 2016 Sep;37(9):12133-12140. Epub 2016 May 24.

PMID:
27220319
25.

Deep Pelvic Surgical Site Infection After Radiotherapy and Surgery for Locally Advanced Rectal Cancer.

Thorgersen EB, Goscinski MA, Spasojevic M, Solbakken AM, Mariathasan AB, Boye K, Larsen SG, Flatmark K.

Ann Surg Oncol. 2017 Mar;24(3):721-728. doi: 10.1245/s10434-016-5621-5. Epub 2016 Oct 20.

PMID:
27766561
26.

Hypoxia-independent gene expression signature associated with radiosensitisation of prostate cancer cell lines by histone deacetylase inhibition.

Jonsson M, Ragnum HB, Julin CH, Yeramian A, Clancy T, Frikstad KM, Seierstad T, Stokke T, Matias-Guiu X, Ree AH, Flatmark K, Lyng H.

Br J Cancer. 2016 Oct 11;115(8):929-939. doi: 10.1038/bjc.2016.278. Epub 2016 Sep 6.

27.

microRNAs as cancer biomarkers.

Flatmark K, Høye E, Fromm B.

Scand J Clin Lab Invest Suppl. 2016;245:S80-3. doi: 10.1080/00365513.2016.1210330. Epub 2016 Aug 9.

PMID:
27542003
28.

Induction of Apoptosis in Intestinal Toxicity to a Histone Deacetylase Inhibitor in a Phase I Study with Pelvic Radiotherapy.

Kalanxhi E, Risberg K, Barua IS, Dueland S, Waagene S, Andersen SN, Pettersen SJ, Lindvall JM, Redalen KR, Flatmark K, Ree AH.

Cancer Res Treat. 2017 Apr;49(2):374-386. doi: 10.4143/crt.2016.080. Epub 2016 Jul 28.

29.

Circulating proteins in response to combined-modality therapy in rectal cancer identified by antibody array screening.

Kalanxhi E, Hektoen HH, Meltzer S, Dueland S, Flatmark K, Ree AH.

BMC Cancer. 2016 Jul 26;16:536. doi: 10.1186/s12885-016-2601-x.

30.

Prognostic significance of S100A4 expression in stage II and III colorectal cancer: results from a population-based series and a randomized phase III study on adjuvant chemotherapy.

Boye K, Jacob H, Frikstad KA, Nesland JM, Maelandsmo GM, Dahl O, Nesbakken A, Flatmark K.

Cancer Med. 2016 Aug;5(8):1840-9. doi: 10.1002/cam4.766. Epub 2016 Jun 8.

31.

Complete cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastasis in Norway: Prognostic factors and oncologic outcome in a national patient cohort.

Frøysnes IS, Larsen SG, Spasojevic M, Dueland S, Flatmark K.

J Surg Oncol. 2016 Aug;114(2):222-7. doi: 10.1002/jso.24290. Epub 2016 May 12.

PMID:
27173150
32.

Systemic release of osteoprotegerin during oxaliplatin-containing induction chemotherapy and favorable systemic outcome of sequential radiotherapy in rectal cancer.

Meltzer S, Kalanxhi E, Hektoen HH, Dueland S, Flatmark K, Redalen KR, Ree AH.

Oncotarget. 2016 Jun 7;7(23):34907-17. doi: 10.18632/oncotarget.8995.

33.

Individual tumor volume responses to short-course oxaliplatin-containing induction chemotherapy in locally advanced rectal cancer - Targeting the tumor for radiation sensitivity?

Flatmark K, Saelen MG, Hole KH, Abrahamsen TW, Fleten KG, Hektoen HH, Redalen KR, Seierstad T, Dueland S, Ree AH.

Radiother Oncol. 2016 Jun;119(3):505-11. doi: 10.1016/j.radonc.2016.02.020. Epub 2016 Mar 8.

PMID:
26968754
34.

Fibromatosis in vertical rectus abdominis myocutaneous flap imitating tumor recurrence after surgery for locally advanced rectal cancer: case report.

Goscinski MA, Hole KH, Tønne E, Ryder T, Grøholt KK, Flatmark K.

World J Surg Oncol. 2016 Mar 3;14:63. doi: 10.1186/s12957-016-0818-4.

35.

Oxaliplatin-containing Preoperative Therapy in Locally Advanced Rectal Cancer: Local Response, Toxicity and Long-term Outcome.

Dueland S, Ree AH, Grøholt KK, Saelen MG, Folkvord S, Hole KH, Seierstad T, Larsen SG, Giercksky KE, Wiig JN, Boye K, Flatmark K.

Clin Oncol (R Coll Radiol). 2016 Aug;28(8):532-9. doi: 10.1016/j.clon.2016.01.014. Epub 2016 Feb 14.

PMID:
26888115
36.

High tumor glycine concentration is an adverse prognostic factor in locally advanced rectal cancer.

Redalen KR, Sitter B, Bathen TF, Grøholt KK, Hole KH, Dueland S, Flatmark K, Ree AH, Seierstad T.

Radiother Oncol. 2016 Feb;118(2):393-8. doi: 10.1016/j.radonc.2015.11.031. Epub 2015 Dec 17.

37.

A Uniform System for the Annotation of Vertebrate microRNA Genes and the Evolution of the Human microRNAome.

Fromm B, Billipp T, Peck LE, Johansen M, Tarver JE, King BL, Newcomb JM, Sempere LF, Flatmark K, Hovig E, Peterson KJ.

Annu Rev Genet. 2015;49:213-42. doi: 10.1146/annurev-genet-120213-092023. Epub 2015 Oct 14. Review.

38.

Enrichment of nuclear S100A4 during G2/M in colorectal cancer cells: possible association with cyclin B1 and centrosomes.

Egeland EV, Boye K, Pettersen SJ, Haugen MH, Øyjord T, Malerød L, Flatmark K, Mælandsmo GM.

Clin Exp Metastasis. 2015 Dec;32(8):755-67. doi: 10.1007/s10585-015-9742-1. Epub 2015 Sep 9.

PMID:
26349943
39.

Sulfamate inhibitor S4 influences carbonic anhydrase IX ectodomain shedding in colorectal carcinoma cells.

Hektoen HH, Ree AH, Redalen KR, Flatmark K.

J Enzyme Inhib Med Chem. 2016 Oct;31(5):779-86. doi: 10.3109/14756366.2015.1069286. Epub 2015 Aug 5.

PMID:
26244271
40.

Early increase in circulating carbonic anhydrase IX during neoadjuvant treatment predicts favourable outcome in locally advanced rectal cancer.

Hektoen HH, Flatmark K, Andersson Y, Dueland S, Redalen KR, Ree AH.

BMC Cancer. 2015 Jul 24;15:543. doi: 10.1186/s12885-015-1557-6.

41.

Prophylactic mesh at end-colostomy construction reduces parastomal hernia rate: a randomized trial.

Lambrecht JR, Larsen SG, Reiertsen O, Vaktskjold A, Julsrud L, Flatmark K.

Colorectal Dis. 2015 Oct;17(10):O191-7. doi: 10.1111/codi.13065.

PMID:
26179984
42.

MRI volumetry for prediction of tumour response to neoadjuvant chemotherapy followed by chemoradiotherapy in locally advanced rectal cancer.

Seierstad T, Hole KH, Grøholt KK, Dueland S, Ree AH, Flatmark K, Redalen KR.

Br J Radiol. 2015 Jul;88(1051):20150097. doi: 10.1259/bjr.20150097. Epub 2015 Apr 22.

43.

Open versus laparoscopic liver resection for colorectal liver metastases (the Oslo-CoMet Study): study protocol for a randomized controlled trial.

Fretland ÅA, Kazaryan AM, Bjørnbeth BA, Flatmark K, Andersen MH, Tønnessen TI, Bjørnelv GM, Fagerland MW, Kristiansen R, Øyri K, Edwin B.

Trials. 2015 Mar 4;16:73. doi: 10.1186/s13063-015-0577-5.

44.

Tumor phosphatidylinositol 3-kinase signaling in therapy resistance and metastatic dissemination of rectal cancer: opportunities for signaling-adapted therapies.

Ree AH, Flatmark K, Saelen MG, Folkvord S, Dueland S, Geisler J, Redalen KR.

Crit Rev Oncol Hematol. 2015 Jul;95(1):114-24. doi: 10.1016/j.critrevonc.2015.01.003. Epub 2015 Jan 12.

PMID:
25624177
45.

Biomarkers of treatment toxicity in combined-modality cancer therapies with radiation and systemic drugs: study design, multiplex methods, molecular networks.

Ree AH, Meltzer S, Flatmark K, Dueland S, Kalanxhi E.

Int J Mol Sci. 2014 Dec 9;15(12):22835-56. doi: 10.3390/ijms151222835. Review.

46.

High expression of the cysteine proteinase legumain in colorectal cancer - implications for therapeutic targeting.

Haugen MH, Boye K, Nesland JM, Pettersen SJ, Egeland EV, Tamhane T, Brix K, Maelandsmo GM, Flatmark K.

Eur J Cancer. 2015 Jan;51(1):9-17. doi: 10.1016/j.ejca.2014.10.020. Epub 2014 Nov 11.

PMID:
25466510
47.

Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium.

Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, Ree AH, Flatmark K, Lyng H, Calzada MJ, Peso LD, Landazuri MO, Görlach A, Flamm H, Kieninger J, Urban G, Weltin A, Singleton DC, Haider S, Buffa FM, Harris AL, Scozzafava A, Supuran CT, Moser I, Jobst G, Busk M, Toustrup K, Overgaard J, Alsner J, Pouyssegur J, Chiche J, Mazure N, Marchiq I, Parks S, Ahmed A, Ashcroft M, Pastorekova S, Cao Y, Rouschop KM, Wouters BG, Koritzinsky M, Mujcic H, Cojocari D.

J Enzyme Inhib Med Chem. 2015;30(5):689-721. doi: 10.3109/14756366.2014.966704. Epub 2014 Oct 27. Review.

PMID:
25347767
48.

B7-H3 expression in colorectal cancer: associations with clinicopathological parameters and patient outcome.

Ingebrigtsen VA, Boye K, Nesland JM, Nesbakken A, Flatmark K, Fodstad Ø.

BMC Cancer. 2014 Aug 20;14:602. doi: 10.1186/1471-2407-14-602.

49.

Biomarkers of histone deacetylase inhibitor activity in a phase 1 combined-modality study with radiotherapy.

Ree AH, Saelen MG, Kalanxhi E, Østensen IH, Schee K, Røe K, Abrahamsen TW, Dueland S, Flatmark K.

PLoS One. 2014 Feb 25;9(2):e89750. doi: 10.1371/journal.pone.0089750. eCollection 2014.

50.

The MOC31PE immunotoxin reduces cell migration and induces gene expression and cell death in ovarian cancer cells.

Wiiger MT, Bideli H, Fodstad O, Flatmark K, Andersson Y.

J Ovarian Res. 2014 Feb 15;7:23. doi: 10.1186/1757-2215-7-23.

Supplemental Content

Loading ...
Support Center